Effective TME-related signature to predict prognosis of patients with head and neck squamous cell carcinoma

Introduction: The tumor microenvironment (TME) is crucial for the development of head and neck squamous cell carcinoma (HNSCC). However, the correlation of the characteristics of the TME and the prognosis of patients with HNSCC remains less known. Methods: In this study, we calculated the immune and stromal cell scores using the "estimate" R package. Kaplan-Meier survival and CIBERSORT algorithm analyses were applied in this study. Results: We identified seven new markers: FCGR3B, IGHV3-64, AC023449.2, IGKV1D-8, FCGR2A, WDFY4, and HBQ1. Subsequently, a risk model was constructed and all HNSCC samples were grouped into low- and high-risk groups. The results of both the Kaplan-Meier survival and receiver operating characteristic curve (ROC) analyses showed that the prognosis indicated by the model was accurate (0.758, 0.756, and 0.666 for 1-, 3- and 5-year survival rates). In addition, we applied the CIBERSORT algorithm to reveal the significant differences in the infiltration levels of immune cells between the two risk groups. Discussion: Our study elucidated the roles of the TME and identified new prognostic biomarkers for patients with HNSCC.

[1]  Shang Gao,et al.  Deficiency in WDFY4 reduces the number of CD8+ T cells via reactive oxygen species-induced apoptosis. , 2021, Molecular immunology.

[2]  G. Cheon,et al.  Glucose metabolic profiles evaluated by PET associated with molecular characteristic landscape of gastric cancer , 2021, Gastric Cancer.

[3]  Junpeng Huang,et al.  FCGR2A Could Function as a Prognostic Marker and Correlate with Immune Infiltration in Head and Neck Squamous Cell Carcinoma , 2021, BioMed research international.

[4]  C. Belka,et al.  Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients , 2021, Theranostics.

[5]  Li Xu,et al.  A novel prognostic mRNA/miRNA signature for esophageal cancer and its immune landscape in cancer progression , 2021, Molecular oncology.

[6]  W. Lei,et al.  A novel immune-related long non-coding RNA signature improves the prognosis prediction in the context of head and neck squamous cell carcinoma , 2021, Bioengineered.

[7]  Xuan Liang,et al.  Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer , 2021, International journal of medical sciences.

[8]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[9]  Runzhe Chen,et al.  Identification of an Immune Gene-Associated Prognostic Signature and Its Association With a Poor Prognosis in Gastric Cancer Patients , 2020, Frontiers in Oncology.

[10]  C. Ottensmeier,et al.  HNSCC: Tumour Antigens and Their Targeting by Immunotherapy , 2020, Cells.

[11]  Ping Huang,et al.  Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma , 2020, Molecular therapy. Nucleic acids.

[12]  A. Vaglio,et al.  FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. , 2020, Rheumatology.

[13]  Xiao-Xue Qin,et al.  BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining , 2020, Frontiers in Oncology.

[14]  Jia Lv,et al.  Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer , 2020, Bioscience reports.

[15]  A. Psyrri,et al.  Biomarkers for immunotherapy response in head and neck cancer. , 2020, Cancer treatment reviews.

[16]  De-Hua Wu,et al.  Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer , 2019, Clinical Cancer Research.

[17]  J. Califano,et al.  Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics , 2019, Clinical Cancer Research.

[18]  A. R. Fernandes,et al.  Targeting Tumor Microenvironment for Cancer Therapy , 2019, International journal of molecular sciences.

[19]  T. K. van den Berg,et al.  FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils , 2019, Front. Immunol..

[20]  B. Solomon,et al.  Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. , 2018, Seminars in cancer biology.

[21]  Shang Gao,et al.  WDFY4 Is Involved in Symptoms of Systemic Lupus Erythematosus by Modulating B Cell Fate via Noncanonical Autophagy , 2018, The Journal of Immunology.

[22]  Giuseppe Curigliano,et al.  Targeting the microenvironment in solid tumors. , 2018, Cancer treatment reviews.

[23]  A. Vaglio,et al.  Association of a polymorphism of the Fcγ-receptor 2A (FCGR2A) gene with chronic periaortitis. , 2018, Clinical and experimental rheumatology.

[24]  M. Davids,et al.  IGHV mutational status testing in chronic lymphocytic leukemia , 2017, American journal of hematology.

[25]  R. Ferris.  Immunology and Immunotherapy of Head and Neck Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Yiping Yang,et al.  Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.

[27]  P. Romero,et al.  C O M M E N T a R Y Open Access , 2022 .

[28]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2013, Nature Medicine.

[29]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[30]  M. Cazzola,et al.  Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors , 2013, Leukemia & lymphoma.

[31]  T. Sørlie,et al.  Subtype‐specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts , 2013, Molecular oncology.

[32]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[33]  W. Yang,et al.  An intronic variant associated with systemic lupus erythematosus changes the binding affinity of Yinyang1 to downregulate WDFY4 , 2012, Genes and Immunity.

[34]  Suzanna Lewis,et al.  Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium , 2011, Briefings Bioinform..

[35]  E. Petretto,et al.  FCGR3B copy number variation is associated with systemic lupus erythematosus risk in Afro-Caribbeans. , 2011, Rheumatology.

[36]  S. Perez,et al.  Cancer immunotherapy , 2009, Critical reviews in clinical laboratory sciences.

[37]  Philippe Froguel,et al.  FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity , 2007, Nature Genetics.

[38]  T. Mayadas,et al.  Fc gamma RIII mediates neutrophil recruitment to immune complexes. a mechanism for neutrophil accumulation in immune-mediated inflammation. , 2001, Immunity.

[39]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[40]  Ruud H. Brakenhoff,et al.  The molecular biology of head and neck cancer , 2011, Nature Reviews Cancer.

[41]  K. Stamatopoulos,et al.  ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia , 2007, Leukemia.

[42]  F. Stevenson,et al.  Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. , 1997, Blood.